Payment overview · 2025
General Payments
$61.71
4 reported records · 2 companies
Healthcare provider profile · identity verified
Sang Kan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1508833872
Verified facts
What the public records show
CMS Open Payments records show Sang Kan, M.D. received $61.71 in general payments during 2025 across 4 reported records.
GlaxoSmithKline, LLC. accounted for 74.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.97 | 74.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.74 | 25.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $61.71 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.97 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
154 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
56 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1384 | 369 |
| Losartan Potassium | Losartan Potassium | 810 | 223 |
| Amlodipine Besylate | Amlodipine Besylate | 718 | 209 |
| Tamsulosin Hcl | Tamsulosin Hcl | 456 | 125 |
| Metoprolol Succinate | Metoprolol Succinate | 445 | 113 |
| Metformin Hcl Er | Metformin Hcl | 415 | 117 |
| Ammonium Lactate | Ammonium Lactate | 299 | 174 |
| Simvastatin | Simvastatin | 295 | 68 |
| Diclofenac Epolamine | Diclofenac Epolamine | 283 | 109 |
| Omeprazole | Omeprazole | 281 | 123 |
| Fluticasone Propionate | Fluticasone Propionate | 271 | 113 |
| Vascepa | Icosapent Ethyl | 252 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 242 | 52 |
| Raloxifene Hcl | Raloxifene Hcl | 236 | 54 |
| Finasteride | Finasteride | 226 | 47 |
| Metformin Hcl | Metformin Hcl | 226 | 66 |
| Jardiance | Empagliflozin | 225 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 205 | 52 |
| Januvia | Sitagliptin Phosphate | 201 | 36 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 189 | 189 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 173 | 38 |
| Telmisartan | Telmisartan | 163 | 33 |
| Allopurinol | Allopurinol | 159 | 31 |
| Gabapentin | Gabapentin | 157 | 45 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 156 | 43 |
| Farxiga | Dapagliflozin Propanediol | 154 | 41 |
| Azelastine Hcl | Azelastine Hcl | 141 | 54 |
| Atenolol | Atenolol | 138 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 122 | 74 |
| Halobetasol Propionate | Halobetasol Propionate | 122 | 85 |
| Azithromycin | Azithromycin | 121 | 103 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 119 | 18 |
| Ozempic | Semaglutide | 118 | 27 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 108 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 46 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 106 | 27 |
| Donepezil Hcl | Donepezil Hcl | 105 | 23 |
| Glimepiride | Glimepiride | 102 | 21 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 101 | 57 |
| Eliquis | Apixaban | 94 | 19 |
| Meloxicam | Meloxicam | 90 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 29 |
| Lisinopril | Lisinopril | 82 | 20 |
| Xarelto | Rivaroxaban | 79 | 18 |
| Mometasone Furoate | Mometasone Furoate | 77 | 24 |
| Rybelsus | Semaglutide | 77 | 22 |
| Glipizide Er | Glipizide | 75 | 18 |
| Bepotastine Besilate | Bepotastine Besilate | 74 | 40 |
| Vemlidy | Tenofovir Alafenamide | 73 | 14 |
| Alendronate Sodium | Alendronate Sodium | 71 | 32 |
| Jentadueto | Linagliptin/Metformin Hcl | 70 | 11 |
| Tradjenta | Linagliptin | 70 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 19 |
| Ciclopirox | Ciclopirox | 68 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 15 |
| Synthroid | Levothyroxine Sodium | 67 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 20 |
| Enalapril Maleate | Enalapril Maleate | 65 | 15 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 65 | 14 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 65 | 12 |
| Nifedipine Er | Nifedipine | 64 | 16 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 62 | 34 |
| Clobetasol Propionate | Clobetasol Propionate | 61 | 31 |
| Montelukast Sodium | Montelukast Sodium | 60 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 56 | 37 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 56 | 30 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 54 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 14 |
| Famotidine | Famotidine | 53 | 22 |
| Ketoconazole | Ketoconazole | 53 | 16 |
| Hydrocortisone | Hydrocortisone | 52 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 35 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | 25 |
| Restasis | Cyclosporine | 49 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 48 | 13 |
| Meclizine Hcl | Meclizine Hcl | 46 | 39 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 12 |
| Mupirocin | Mupirocin | 45 | 30 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 12 |
| Dutasteride | Dutasteride | 44 | suppressed |
| Ibuprofen | Ibuprofen | 44 | 37 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 42 | 11 |
| Ezetimibe | Ezetimibe | 42 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 12 |
| Lactulose | Lactulose | 41 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 14 |
| Folic Acid | Folic Acid | 40 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 13 |
| Lidocaine | Lidocaine | 39 | 15 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 38 | 16 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 18 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Procto-Med Hc | Hydrocortisone | 32 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | 14 |
| Carvedilol | Carvedilol | 31 | 13 |
| Ciclopirox | Ciclopirox Olamine | 31 | 14 |
| Entecavir | Entecavir | 30 | suppressed |
| Methimazole | Methimazole | 30 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 28 | 11 |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Estradiol | Estradiol | 28 | 16 |
| Glipizide | Glipizide | 27 | suppressed |
| Prolia | Denosumab | 26 | 20 |
| Mupirocin | Mupirocin Calcium | 25 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Colchicine | Colchicine | 20 | 11 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 19 | 11 |
| Flunisolide | Flunisolide | 19 | suppressed |
| Fluocinonide | Fluocinonide | 19 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Furosemide | Furosemide | 18 | suppressed |
| Letrozole | Letrozole | 18 | suppressed |
| Nexium | Esomeprazole Magnesium | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 11 |
| Prevident 5000 Sensitive | Sodium Fluoride/Potassium Nit | 12 | suppressed |
| Alogliptin-Metformin | Alogliptin Benz/Metformin Hcl | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $61.71 · 4 records | GlaxoSmithKline, LLC. | BREZTRI, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error